Cite
HARVARD Citation
Poeschel, V. et al. (2019). Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 394 (10216), pp. 2271-2281. [Online].